Australia has officially launched its presence at BIO Asia–Taiwan 2025, with a dynamic delegation of 26 leading life sciences organisations spearheaded by the Australian Trade and Investment Commission (Austrade). Running from 23–25 July, the live event brings together global biotech trailblazers, with Australia firmly in the spotlight as a trusted partner in clinical development and health innovation.
Located at Booth M608, TaiNEX 1, the Australian Pavilion offers visitors a unique window into the nation’s end-to-end clinical research capabilities—from early-phase and hospital-based trials to regulatory affairs, real-world data solutions, and beyond.
The Australian delegation features organisations spanning:
Clinical Research Organisations (CROs) with regional expertise
Bioanalytical testing and regulatory consulting services
Patient recruitment and engagement technologies
Medtech and pharmaceutical development
R&D strategy and market access advisory
This collective showcases Australia’s globally recognised strengths: world-class infrastructure, an efficient and ethical regulatory system, diverse patient populations, and strong government backing. It’s no surprise Australia is increasingly the destination of choice for global clinical trials and translational health partnerships.
“Australia’s presence here is not just about promotion—it’s about partnerships. We’re inviting the global life sciences community to collaborate, innovate, and grow with us,” said a spokesperson from Austrade.
Explore how Australian organisations are redefining the clinical trial landscape, forging global collaborations, and delivering impactful health outcomes across the Asia-Pacific.
